Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

URAT1 inhibitor and application thereof

A compound and pharmaceutical technology, applied in the field of URAT1 inhibitor compounds, can solve the problems of lack of anti-gout drugs, adverse reactions, and high incidence of serious adverse events

Pending Publication Date: 2022-03-22
JIANGSU ATOM BIOSCI & PHARMA CO LTD
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical trials have shown that Lesinurad has a variety of toxic and side effects: (1) The drug may cause fatal cardiovascular disease, non-fatal myocardial infarction or brain exhaustion in patients with moderately severe cardiovascular adverse reactions
(2) Adverse reactions related to renal function will occur after the initial treatment of Lesinurad. When 400 mg is taken alone, the incidence of serious adverse events is the highest. Therefore, high-dose monotherapy is prohibited clinically, and renal function needs to be tested regularly before and after treatment.
However, due to the lack of good anti-gout drugs in the market, they are still widely used in more than 20 countries including China, Germany, Japan, Brazil, and New Zealand

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • URAT1 inhibitor and application thereof
  • URAT1 inhibitor and application thereof
  • URAT1 inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Embodiment 1: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-2H-indazol-3-yl)methanone (6)

[0063]

[0064] Step A: A mixture containing indazole (5.00 g, 42.3 mmol), ethyl iodide (13.2 g, 90.3 mmol), potassium hydroxide (5.50 g, 98.0 mmol) and ethanol (60 mL) was stirred at 65 °C for 5 hours . Cool to room temperature and filter to remove insoluble matter. The solvent was evaporated under reduced pressure, then water (30 mL) was added, extracted with dichloromethane (20 mL×3), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the product was purified by column chromatography (200-300 mesh silica gel, ethyl acetate:petroleum ether=1:20-1:5 elution) to obtain 2-ethyl-2H-indazole (1) (1.56g) and 1-ethyl-1H-indazole (2) (3.06g). The yields were 25.2% and 49.5%, respectively. Compound 1: 1 H NMR (DMSO-d 6 , 400MHz) δ8.37(s, 1H), 7.69(d, J=8.4Hz, 1H), 7.60(d, J=8.4Hz, 1H), 7.24-7.20(m, 1H), 7.05-7.01(m , 1H), 4.46 ...

Embodiment 2

[0069] Example 2: Synthesis of 2,6-dibromo-4-[(2-ethyl-2H-indazol-3-yl)hydroxymethyl]phenol (7)

[0070]

[0071] Sodium borohydride (90mg, 2.38mmol) was added to a solution of compound 6 (100mg, 0.236mmol) in methanol (10mL). After the addition was complete, the resulting mixture was stirred at reflux for 30 minutes, and then sodium borohydride (90mg, 2.38mmol) was added. ), stirring was continued for 1 hour under reflux. Water (20 mL) was added, the pH value was adjusted to 6-7 with 2M aqueous citric acid solution, extracted with ethyl acetate (20 mL×3), the combined organic phases were washed with water (20 mL), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the product was purified by column chromatography (200-300 mesh silica gel, ethyl acetate:petroleum ether=1:20-1:3 elution) to obtain 2,6-dibromo-4-[(2 -Ethyl-2H-indazol-3-yl)hydroxymethyl]phenol (7). 1 H NMR (DMSO-d 6 , 400MHz) δ9.99(s, 1H), 7.55(d, J=8.8Hz, 1H), 7.5...

Embodiment 3

[0072] Example 3: Synthesis of (3,5-dibromo-4-hydroxyphenyl)(1-ethyl-1H-indazol-3-yl)methanone (10)

[0073]

[0074] Step A: A mixture containing compound 2 (2.59g, 17.7mmol), p-methoxybenzoyl chloride (3.02g, 17.7mmol) and anhydrous aluminum chloride (3.54g, 26.6mmol) was stirred overnight at 105°C . Cool to room temperature, add water (30 mL) and ethyl acetate (30 mL), and stir for about 5 minutes. The layers were separated, the aqueous layer was extracted with ethyl acetate (10 mL×3), the combined organic phases were washed with water (15 mL), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the product was purified by column chromatography (200-300 mesh silica gel, ethyl acetate:petroleum ether = 1:25-1:15 elution) to obtain (1-ethyl-1H-indazole-3 -yl)(4-methoxyphenyl)methanone (8) (990 mg). The yield was 21.1%. 1 H NMR (DMSO-d 6 , 400MHz) δ8.34-8.29(m, 3H), 7.88(d, J=8.4Hz, 1H), 7.56-7.52(m, 1H), 7.41-7.37(m, 1H), 7....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal chemistry, and particularly relates to a URAT1 inhibitor and application thereof, in particular to a compound with a structure shown as a formula (I) or a formula (II) or pharmaceutically acceptable salt thereof. Experiments show that the compound provided by the invention has a very good inhibition effect on hURAT1 transport uric acid in HEK293 transfected cells, and the compound has a good application prospect in the aspect of treating hyperuricemia or gout.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and specifically relates to a class of URAT1 inhibitor compounds and applications of the compounds. Background technique [0002] Gout is a metabolic disease caused by hyperuricemia. When the purine metabolism in the human body is disordered or excessive intake of high-purine foods leads to increased production of uric acid, and the kidneys cannot excrete uric acid smoothly, resulting in blood uric acid concentration exceeding the normal level and reaching saturation, a large amount of urate accumulates and crystallizes. Deposited in joints, tendons, kidneys and other parts, eventually leading to recurrent arthritic pain (Richette P, Bardin T. Gout. Lancet. 2010, 375(9711): 318-328). Hyperuricemia is clinically defined when the blood uric acid concentration in men is >7 mg / dL or in women is greater than 6 mg / dL. About 80-85% of patients with hyperuricemia are caused by poor excretion of ur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D231/56C07D471/04A61K31/416A61K31/437A61P19/06
CPCC07D231/56C07D471/04
Inventor 史东方周禾朱江华李鹏飞承曦杨艳顾杰吴帆
Owner JIANGSU ATOM BIOSCI & PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com